{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of the confidence interval not calculable due to a low number of participants reaching PD or all-cause death.","groupId":"OG000","lowerLimit":"3.7","upperLimit":"NA","value":"9.5"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"12.0","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Duration of response (DOR) was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for progression-free survival.","dispersionType":"95% Confidence Interval","groups":[{"description":"Best Supportive Care: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).\n\nOptional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).","id":"OG000","title":"Best Supportive Care"},{"description":"Carfilzomib: 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \\[Days 1, 2, 8, 9, 15, 16\\] for individual subjects).","id":"OG001","title":"Carfilzomib"}],"paramType":"MEDIAN","populationDescription":"The intent to treat (ITT) population comprised randomized participants who achieved a best overall response of PR or better only.","reportingStatus":"POSTED","timeFrame":"From the time achieving response through the final analysis data cutoff with longest follow-up time of approximately 29 months.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}